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SUMMARY
Despite recent developments in the inventory management, introduction of  electronic drug trolleys and cabinets, 
color coding of  the filled syringes and many more interventions, medication errors could not be eliminated. The 
most common of  these are syringe swap and human errors regarding wrong drug administration due to look-alike 
drug containers or sound-alike names of  the drugs belonging to diverse groups. Many of  the fatalities, that occur 
in third world countries due to these causes, go unnoticed and unregistered. This special article complements two 
special editorials on the same topic by Professor Joseph D. Tobias et al and Professor Robert Stoelting, a case 
report, a patient’s perspective and a ‘Cliniquiz’ being published in the current issue of  the journal. It discusses 
salient features of  this issue as well as preventive measures and recommendations.
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INTRODUCTION
Medication names that look similar or sound similar have 
been identified as a potential source of  error in health care 
systems. Medications in which packaging is visually similar 
to another product or medication comes in the category of 
look-alikes. Medications for which generic or trade names 
of  the product or medication sounds similar in the spoken 
or written words are categorized as sound-alike drugs. 
Look-alike and sound-alike (LASA) drug names can lead 
to the unintended interchange of  drugs that can result in 
patient injury or death. 
The existing medication-use system face problems because 
its safety depends on human perfection and systems that 
rely on human perfection are most likely to fail as no human 
can function perfectly all the time. Even the best-trained 
and most careful people occasionally make mistakes. Other 
hazardous industries also train and test for perfection, 
but they do not rely on it. Safety is achieved by designing 
systems, processes, and tasks that prevent mistakes.
Simplicity, standardization, differentiation, lack of 
duplication, and unambiguous communication are some of 
concepts that are relevant to the medication-use process. 
These principles have often been ignored in the naming, 
labeling, and packaging of  medications. The consequences 
are predictable. Bad names, bad labels, and bad packages 
result in accidents waiting to happen.1
Medication errors are the most common cause of  patient 
injuries in hospitals. Adverse drug events, about half  of 
which are due to medication errors, accounted for 19% 
of  all injuries identified by the population based Harvard 
Medical Practice Study.2 An estimated 2-7% of  patients 
admitted to hospitals experience a serious medication error 
(one that has the potential to cause injury).2 One study at 
a teaching hospital yielded an estimate that, on average, 
each preventable adverse drug event (ADE) resulted in an 
additional stay of  4.6 days and a cost of  $4685.3 
The purpose of  this article is to highlight medication errors 
related to LA-SA medications in order to create awareness 
among medical practitioners The intent is to encourage 
thought to formulate a system to prevent this preventable 
cause of  morbidity and mortality in our patients. This article 
will discuss medication errors and the key elements that 
affect the medication error, bench marking for medication 
error, preventable measures like “Tall man lettering” to 
differentiate between look-alike drugs, nature and causes 
of  look-alike drugs, potential solution to prevent this error 
and barrier in the implementation of  these problem solving 
measures. In the end we will discuss the way forward and 
recommendations for prevention of  medical errors related 
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to LA-SA medications and similar packages.
DEFINITIONS 
A medication error is “any error occurring in the 
medication use process”.4 The National Coordinating 
Council for Medication Error and Prevention has 
approved the following as its working definition of 
medication error: “... any preventable event that may 
cause or lead to inappropriate medication use or patient 
harm, while the medication is in the control of  the 
health care professional, patient, or consumer. Such 
events may be related to professional practice, health care 
products, procedures, and systems including: prescribing; 
order communication; product labeling, packaging and 
nomenclature; compounding; dispensing; distribution; 
administration; education; monitoring; and use.”5
MEDICATION PROCESS
There are a number of  key elements that affect the 
medication-use process including;
•	 Patient information
•	 Drug information
•	 Communication of  drug information
•	 Drug labeling, packaging and nomenclature
•	 Drug storage, stock, standardization, and distribution
•	 Drug device acquisition, use and monitoring
•	 Environmental factors
•	 Staff  competency and education: 
•	 Patient education
•	 Quality processes and risk management:
As mentioned in the list, drug labeling, packaging and 
nomenclature is one of  the key elements. Drug names 
that look-alike or sound-alike, as well as products that have 
confusing drug labeling and non-distinct drug packaging 
significantly contribute to medication errors. The incidence 
of  medication errors is reduced with the use of  proper 
labeling and the use of  unit dose systems within hospitals. 
It is the interrelationships among all these key elements 
that form the structure within which medications are used.
National medication error rate and benchmarking for 
medication error:
It is difficult to have a national medication error rate, as the 
working of  each organization and hospital in any country 
is different. Therefore true or universal bench marking is 
generally not possible. Even for individual organizations, 
it is difficult to have a true rate as most systems rely on 
voluntary reporting of  actual events or near miss events. 
The problem with voluntary reporting lies in the fact that 
the actual number of  events could be much higher than 
the reported event. In addition, organizations having good 
reporting systems have a high number of  events and can be 
safer as compared to organizations having fewer reported 
incidents which could be due to poor reporting system.
Like all errors in health care, those that result from 
confusing names or packages are rarely reported unless 
they are known to result in death or serious injury. There 
have been no rigorous studies. A 2001 report by United 
State Pharmacopeia (USP) convention indicated that 
confusion over drug names accounted for 15% of  errors 
reported to the USP’s Medication Errors Reporting 
look-alike and sound-alike drugs
1. alDACTONE 2. humALOG 
3. alDOMET 4. humULIN 
5. alODORM 6. hydrALAZINe 
7. alphaprESS 8. hydrOCHLOROTHIAZIDe 
9. alphaprIL 10. ketALAR 
11. amARYl 12. ketOROLAC 
13. amOXIl 14. laRGACTIl 
15. amIODAROne 16. laMICTAl
17. amLODIPIne 18. methADONe 
19. amITRIPTYLIne 20. methYLPHENIDATe 
21. amINOPHYLLIne 22. meTOhexal 
23. aPomine 24. meLLIhexal 
25. aVomine 26. morphine
27. arABLOC 28. HYDROmorphone
29. aTRopt 30. NEOral 
31. aZopt 32. INDEral 
33. azATHIOPRINE 34. niFEDIPine 
35. ERYthromycin 36. niMODIPine 
37. azITHROMYCIN 38. niZATIDine 
39. bisOPROLOl 40. proMETHazine 
41. bisACODYl 42. proCHLORPERazine 
43. OXCARBazepine 44. propRANOLol 
45. CARBAMazepine 46. propOFol 
47. carbIMAZOLe 48. tEGRETOl 
49. caRVEDILOl 50. tRENTAl 
51. caPTOPRIl 52. tEMOdal
53. celAPRAM 54. tRAMadol 
55. DOBUTamine 56. tORadol
57. DOPamine 58. trimEPRAZINE 
59. DEPO-medrol 60. trimIPRAMINE 
61. SOLU-medrol 62. CLONazepam 
63. depo-PROVERA 64. DIazepam 
65. solu-CORTEF 66. OXazepam
67. SOLU-medrol 68. diPYRIDAMOLe 
69. diPRIVan 70. diSOPYRAMIDe 
Table 1: Tall Man lettering for some drugs
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Program (MERP) from January 1996 through December 
2000. The same report lists 749 drug names reported to 
MERP because they sound alike when communicated 
orally or look alike in print or when written.1The increasing 
potential for LASA medication errors was highlighted in 
the Joint Commission’s Sentinel Event Alert6 in the United 
States of  America and was incorporated into the Joint 
Commission’s National Patient Safety Goals.7
Tall Man Lettering 
Tall Man lettering involves highlighting the dissimilar letters 
in two names to aid in distinguishing between the two 
for example HumaLOG and HumuLIN, oxyCODONE 
and OxyCONTIN; ceFAZolin and cefTRIAXONE; 
and FLUoxetine and DULOXetine; clonazePAM and 
LORazePAM.
In addition to the institution for safe medical process 
(ISMP), several studies have shown that highlighting 
sections of  drug names using tall man (mixed case) letters 
can help distinguish similar drug names, making them less 
prone to mix-ups.8-13 ISMP, FDA, the Joint Commission, 
and other safety conscious organizations have promoted the 
use of  tall man letters as one means of  reducing confusion 
between similar drug names. To promote standardization, 
ISMP has created a list of  Look-Alike Drug Name Sets with 
Recommended Tall Man Letters.14 A list of  some drugs to 
which anesthesiologists are usually familiar is given in Table 
1.
Look-Alike Ampoules
Look-alike ampoules and vials are a reality; simply because 
there are so few designs and colors to choose from; so 
many injectable drugs to dispense; and the issue is not 
exactly at the forefront of  stakeholders’ agenda. A few 
investigators have gone on to advocate uniform ampoules 
for all drugs in order to force the users to read their 
labels carefully before drawing up the medication.15  This 
view is, however, not supported by the majority who 
advocate distinct labeling to facilitate identification at the 
time of  drawing the drug.16,17  Whereas drug regulatory 
authorities mandate the pharmaceutical companies to 
display requisite information on each ampoule/vial of 
the drug; the instructions on distinct labeling are more 
explicit for the packages while they are less binding for 
components within the package. Medicine and Healthcare 
Regulatory Agency of  UK suggest an “Innovative pack 
design that may incorporate the judicious use of  color 
is to be encouraged to ensure accurate identification 
of  the medicine”.18 However, similar instructions for 
individual ampoules are missing. The medication safety 
conference hosted by the Anesthesia Patient Safety 
Foundation (APSF), while recognising the role of  look-
alike vials in drug errors, did not include a demand for the 
pharmaceutical industry to develop distinct looking vials/
ampoules in its recommendations.19  
Role of  pharmaceutical companies
The factors for the medication-use process needs to be 
simple and should follow the principle of  standardization, 
differentiation and lack of  duplication. Unfortunately, 
these principles are not followed in drug naming, labeling, 
and packaging. Instead, current methods are based on 
long-standing commercial considerations and bureaucratic 
procedures. Drug companies have to undergo a lengthy 
and complex process for naming a marketable drug 
that involves submission of  a new chemical entity and 
patent application, generic naming, brand naming, FDA 
review, and final approval. Pharmaceutical companies 
seek the fastest possible approval and may believe that 
the incremental benefit of  evaluating human factors is 
small. “Trade dress” is the concept that underlies labeling 
and packaging issues for the drug industry. Even FDA 
standards do not require application of  human factor 
principles, therefore drug names, labels, and packages are 
selected and designed in accordance with the marketplace 
rather than for practice conditions.
There are well-known, effective methods for minimizing 
confusion and making it more difficult to commit medical 
errors. However, pharmaceutical companies tend to resist 
implementing these methods because of  the complexity, 
cost, concern about increasing already cumbersome 
regulations, fear of  liability exposure, and loss of 
competitive advantage. Therefore, some new approach or 
combination of  approaches is required to help us discover 
and continually define methods for improving safety.
Pharmaceutical companies on the other hand do not seem 
to own the problem of  safety associated with look-alike 
drugs; they are satisfied with meeting minimum regulatory 
requirements for labeling and packaging.20 Drug labeling 
and packing rules (1986) of  the Government of  Pakistan 
state “Manner of  Labeling: The following particulars 
shall appear either in print or in writing in inedible ink 
in a conspicuous manner on a label of  the innermost 
container of  drug and also on the package in which such 
container is packed namely”.21 Recent changes in the way 
the ampoules of  injectable drugs are labeled in Pakistan 
have increased the number of  look-alike drugs, which is 
likely to increase the risk of  drug errors. Drug labels were 
largely printed as stickers on the ampoules; number of 
distinct combinations of  background, color and print for 
individual drugs or groups of  drugs with paper stickers 
facilitated identification of  drugs during high use or crisis 
situations. More recently, names of  the drugs and other 
information is imprinted on the ampoule. With a choice 
between transparent and dark brown glass and four ink 
colors, the number of  combinations is small. Reading the 
small print particularly in yellow or white colors against a 
special article
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glass background is a test for an anesthesiologist’s vision. 
Interestingly, healthcare professionals have either not 
noticed this change or accepted it as inevitable. It appears 
we have to live in a world of  “look alike” drug containers 
and devise strategies to minimise errors in the face of 
this menace. One solution is to keep the vials/ampoules 
in their packages, only removing them at when they are 
ready to be drawn. Packages are easier to identify than 
ampoules or vials.  However, this may be cumbersome if 
the medications are kept in a drug tray as the packages are 
generally much larger than the vials. Individual packaging 
may also significantly increase the cost of  medications 
when compared to bulk packaging of  vials.  
FINDING THE SOLUTIONS
Prevention of  errors was traditionally ascribed to 
individuals responsible for patient care; based on two 
myths, which have been challenged more recently:22
•	 If  people try hard enough, they will not make any 
errors.
•	 If  we punish people when they make errors, they will 
make fewer of  them.
The anesthesia practitioner is responsible for prescribing, 
preparing, administering and recording drugs; working 
long hours, with distractions and often in crisis-like 
situations. Fraind and colleagues demonstrated multiple 
flaws in preparation, handling and administration of 
intravenous drugs and infusions by experienced anesthesia 
personnel in University Hospitals,23 emphasising the need 
to improve the systems. A comprehensive approach to 
prevent drug errors in anesthesia practice would involve 
standard prescribing, storing, dispensing, drawing, and 
drug administration practices. Experience with the airline 
industry has demonstrated that the frequency of  errors can 
be reduced by breaking down the task into components 
and repeated drills.   
A seven step approach to patient safety advocated by the 
National Patient Safety Foundation of  the UK stresses the 
need to build a culture of  safety; provide support to the 
staff; promote reporting; learn and share safety lessons; 
and implement solutions to prevent harm among the key 
features of  safe practice.24 Organisational culture that 
fosters a culture of  safety encourages shared responsibility 
instead of  blame; where employees are encouraged to 
voice their safety concerns and the emphasis is on evolving 
systems based on safe practice instead of  expecting 
humans not to make mistakes.  The implication of  such 
processes has been shown to have decrease the number of 
critical incidents and near misses.25
Incident reporting is central to improving quality of  care 
and minimising errors; the incidence of  errors is lower 
in organisations with a strong system of  reporting. The 
purpose of  these reports is not to assign responsibility, 
but to take corrective measures for the future. Reports, 
however, do have their limitations; all of  the incidents are 
not reported and it is not agreed on what is the appropriate 
denominator; total number of  anesthetics or total number 
of  drug administrations. Under-reporting was highlighted 
in two ethnographic studies that looked into the practice 
of  intravenous drug administration.  This study identified 
a 49% and 48% error rate respectively during preparation 
and administration of  drugs in UK and German Hospitals. 
These errors were severe in a small number of  cases and 
were identified and corrected by another person in the 
majority of  cases. 
The reported frequency of  drug errors is, however, very 
low, which makes it difficult to generate class one evidence 
to prove the efficacy of  an intervention or a group of 
interventions. Recommendations are thus based largely 
on data extracted from incident reports and hospital 
information systems based on these reports. 
RECOMMENDATIONS
Jensen et al analysed common practices advocated to 
prevent drug errors. A panel of  experts was invited to 
rate the strength of  recommendation, based on their 
expert opinion in the absence of  direct evidence. This was 
followed by a validation study. The recommendations were 
analysed and weighted according to expert opinion; grade 
of  recommendation depended on the agreement between 
the panel of  experts.26  
1. The label on any drug ampoule or syringe should 
be read carefully before a drug is drawn or injected. 
Strongly recommended. 
2. The contents of  the label on the ampoule should 
be optimised according to agreed standard. Strongly 
recommended.
3. Syringes should be labeled (always or almost always). 
Strongly recommended.
4. Formal organisation of  drug drawers and workplace. 
Strongly recommended. 
5. Labels should be checked specifically by a second 
person or device. Recommended.
6. Errors in intravenous drug administration during 
anesthesia should be reported or reviewed. 
Recommended. 
7. Management of  inventory should focus on 
minimising the risk of  drug error by appointing a 
safety officer or pharmacist in the OR. Recommended.
8. Similar packaging and presentation of  drugs 
contribute to drug error and should be avoided 
where possible. Recommended. 
look-alike and sound-alike drugs
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9. Drugs should be presented in prefilled syringes 
(where possible) rather than ampoules. Possibly 
recommended. 
10. Drugs should be drawn up by the anesthetist who 
should label it. Possibly recommended.
11. Color coding of  drug class according to an agreed 
national or international standard should be used. 
Possibly recommended.
12. Coding by syringe position or size or needle on the 
syringe should be used. Possibly recommended.       
Experts disagreed on whether drugs should be prefilled 
or drawn at the time of  administration; both were 
recommended in view of  difference of  opinion. 
There were 81 error reports and 40 pre-error reports, 
which were analyzed by reviewers to validate these 
recommendations. In their opinion, strategies number 
6 and 12 were ineffective in preventing these errors, 
whereas, recommendations 1, 5 and 9 were most effective 
in preventing them. Some of  the incidents could not have 
been prevented with any of  the strategies. These mainly 
involved human factors that included inattention, haste, 
distraction or fatigue. 
Color coding has been a subject of  debate. A study 
looking into the impact of  color coded syringe labels on 
the frequency of  drug errors failed to show a benefit, but 
this could be explained due to a 0.11% reported drug error 
rate.27 The Council for Scientific Affairs (CSA) of  American 
Medical Association has expressed their reservations on 
the efficacy of  color coding on the grounds that there are 
a limited number of  discernible colors; colors may fade; 
and there is a high prevalence of  color blindness among 
anaesthetists.28 Merry and colleagues describe this as error 
management rather than prevention. In the case of  an 
error in reading the name, color coding would ensure that 
a drug of  same class was administered, thus reducing the 
potential for harm through interclass error.29
Independent double check is not included in the Jensen 
et al. list, but it has been shown to prevent errors of 
drug administration.30 It is desirable that drugs should be 
checked by two persons independently and ideally verbally 
verified before drawing and administration.
What can anesthesia departments do to prevent/
manage drug errors?
•	 Develop departmental protocols for prescription, 
storage, drawing, administration and documentation 
of  intravenous drugs in the OR and PACU.
•	 Promote a culture of  reporting drug related errors, 
no matter how trivial the error and whatever the 
outcome. 
•	 Each report should initiate a full cycle of  analysis → 
Solution development → Implementation → Audit 
and monitoring → Feedback → Reporting
•	 Accept that human beings make errors, but do not 
tolerate deliberate ignorance/breach of  protocol
What can anesthesia consultants do to prevent/
manage drug errors?
•	 Let everyone be aware that drug errors are a universal 
reality
•	 Provide a leadership role by developing a culture of 
safety; reporting errors and encouraging others to do 
so.
SUMMARY
Problems with the naming, labeling, and packaging of 
drugs contribute to errors that cause patient injuries and 
deaths. Names, labels, and packages are not selected and 
designed in accordance with human factors principles. 
FDA standards do not require application of  these 
principles, the pharmaceutical industry has resisted change, 
and private sector initiatives have had only limited success.
When we say drug errors are uncommon, it is mostly 
because they are underreported. Safety should not rely on 
human perfection, but rather focus on designing systems, 
processes, and tasks that make it difficult for people to make 
mistakes at all. System based strategies; an institutional 
culture that fosters reporting of  errors and encourages 
everyone to identify potential sources of  errors are means 
to prevent these incidents.
special article
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